P Clezardin

Summary

Country: France

Publications

  1. pmc Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer
    Ahmed Boucharaba
    INSERM, U403, 69372 Lyon Cedex 08, France
    J Clin Invest 114:1714-25. 2004
  2. ncbi request reprint Potential anticancer properties of bisphosphonates: insights from preclinical studies
    Philippe Clezardin
    Institut National de la Santéet de la Recherche Médicale, Research Unit UMR 1033, Facultede Medecine Lyon Est domaine Laennec, 8 rue Guillaume Paradin, F 69372 Lyon, France
    Anticancer Agents Med Chem 12:102-13. 2012
  3. doi request reprint Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class
    Philippe Clezardin
    INSERM, Research Unit U664, University of Lyon 1, Faculty of Medicine Lyon Est domaine Laennec, Rue Guillaume Paradin, 69372 Lyon Cedex 08, France
    Bone 48:71-9. 2011
  4. doi request reprint [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]
    Philippe Clezardin
    INSERM, UMR1033, 69372 Lyon, FranceInserm, UMR1033, 69372 Lyon, FranceInserm, UMR1033, 69372 Lyon, France
    Bull Cancer 98:837-46. 2011
  5. pmc Therapeutic targets for bone metastases in breast cancer
    Philippe Clezardin
    INSERM, UMR1033, F 69008 Lyon, France
    Breast Cancer Res 13:207. 2011
  6. doi request reprint Bisphosphonates in preclinical bone oncology
    Philippe Clezardin
    INSERM, UMR, IFR, Lyon, France
    Bone 49:66-70. 2011
  7. ncbi request reprint Nitrogen-containing bisphosphonates and cancer immunotherapy
    P Clezardin
    INSERM, Research Unit U664, University of Lyon 1, Faculty of Medicine Laennec, Rue Guillaume Paradin, 69372 Lyon Cedex 08, France
    Curr Pharm Des 16:3007-2014. 2010
  8. ncbi request reprint Integrins in bone metastasis formation and potential therapeutic implications
    P Clezardin
    INSERM, UMR 664, IFR62, Lyon, F 69372, and Universite Lyon 1, Villeurbanne, F 69622, France
    Curr Cancer Drug Targets 9:801-6. 2009
  9. doi request reprint [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic]
    P Clezardin
    INSERM, unité U664, Faculté de médecine Lyon Est domaine Laennec, 69372 Lyon, France
    Bull Cancer 97:937-49. 2010
  10. ncbi request reprint The antitumor potential of bisphosphonates
    Philippe Clezardin
    Laennec School of Medicine, Lyon, France
    Semin Oncol 29:33-42. 2002

Collaborators

Detail Information

Publications37

  1. pmc Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer
    Ahmed Boucharaba
    INSERM, U403, 69372 Lyon Cedex 08, France
    J Clin Invest 114:1714-25. 2004
    ..Overall, our data suggest that, at the bone metastatic site, tumor cells stimulate the production of LPA from activated platelets, which enhances both tumor growth and cytokine-mediated bone destruction...
  2. ncbi request reprint Potential anticancer properties of bisphosphonates: insights from preclinical studies
    Philippe Clezardin
    Institut National de la Santéet de la Recherche Médicale, Research Unit UMR 1033, Facultede Medecine Lyon Est domaine Laennec, 8 rue Guillaume Paradin, F 69372 Lyon, France
    Anticancer Agents Med Chem 12:102-13. 2012
    ..g., multiple myeloma]). This review article summarizes the preclinical anticancer activities of bisphosphonates in various cancer types and evaluates their potential contributions to the recently demonstrated clinical effects...
  3. doi request reprint Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class
    Philippe Clezardin
    INSERM, Research Unit U664, University of Lyon 1, Faculty of Medicine Lyon Est domaine Laennec, Rue Guillaume Paradin, 69372 Lyon Cedex 08, France
    Bone 48:71-9. 2011
    ..This review examines the current insights and fronts of ongoing preclinical research on N-BPs' antitumor activity...
  4. doi request reprint [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]
    Philippe Clezardin
    INSERM, UMR1033, 69372 Lyon, FranceInserm, UMR1033, 69372 Lyon, FranceInserm, UMR1033, 69372 Lyon, France
    Bull Cancer 98:837-46. 2011
    ..Inhibition of RANK/RANKL system may therefore offer new therapeutic perspectives for the treatment of primitive and secondary bone cancers...
  5. pmc Therapeutic targets for bone metastases in breast cancer
    Philippe Clezardin
    INSERM, UMR1033, F 69008 Lyon, France
    Breast Cancer Res 13:207. 2011
    ..The clinical exploitation of these bone-targeted agents will provide oncologists with novel therapeutic strategies for the treatment of skeletal lesions in breast cancer...
  6. doi request reprint Bisphosphonates in preclinical bone oncology
    Philippe Clezardin
    INSERM, UMR, IFR, Lyon, France
    Bone 49:66-70. 2011
    ..This review examines the current evidence and provides insights into ongoing preclinical research on anticancer activities of these bisphosphonates in animal models of tumorigenesis and metastasis...
  7. ncbi request reprint Nitrogen-containing bisphosphonates and cancer immunotherapy
    P Clezardin
    INSERM, Research Unit U664, University of Lyon 1, Faculty of Medicine Laennec, Rue Guillaume Paradin, 69372 Lyon Cedex 08, France
    Curr Pharm Des 16:3007-2014. 2010
    ..In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy...
  8. ncbi request reprint Integrins in bone metastasis formation and potential therapeutic implications
    P Clezardin
    INSERM, UMR 664, IFR62, Lyon, F 69372, and Universite Lyon 1, Villeurbanne, F 69622, France
    Curr Cancer Drug Targets 9:801-6. 2009
    ..Here, we review the role of integrins in bone metastasis formation and present evidence that the use of integrin-targeted therapeutic agents may be an efficient strategy to block tumor metastasis...
  9. doi request reprint [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic]
    P Clezardin
    INSERM, unité U664, Faculté de médecine Lyon Est domaine Laennec, 69372 Lyon, France
    Bull Cancer 97:937-49. 2010
    ....
  10. ncbi request reprint The antitumor potential of bisphosphonates
    Philippe Clezardin
    Laennec School of Medicine, Lyon, France
    Semin Oncol 29:33-42. 2002
    ..Research is ongoing to fully elucidate these biochemical mechanisms, and well-designed clinical trials are planned to investigate the antitumor potential of modern nitrogen-containing bisphosphonates in the clinical setting...
  11. ncbi request reprint Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction
    P Clezardin
    INSERM U 234, , Lyon, France
    Cancer Res 51:2621-7. 1991
    ..6 x 10(6) cells/ml).(ABSTRACT TRUNCATED AT 400 WORDS)..
  12. pmc The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases
    Ahmed Boucharaba
    Institut National de la Santé et de la Recherche Médicale INSERM U664, 69372 Lyon, France
    Proc Natl Acad Sci U S A 103:9643-8. 2006
    ..Overall, these results suggest that inhibition of platelet-derived LPA action on LPA(1) expressed by tumor cells may be a promising therapeutic target for patients with bone metastases...
  13. ncbi request reprint Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain
    B Merle
    INSERM Research Unit 403, Pavillon F, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    J Cell Biochem 75:538-46. 1999
    ..dermatan-sulfate chains), and is independent of a steric hindrance effect exerted by its glycosaminoglycan side chains...
  14. ncbi request reprint Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1
    B Merle
    INSERM Research Unit 403, Hopital Edouard Herriot, Lyon, France
    J Cell Biochem 67:75-83. 1997
    ..Overall, these data indicate that modulation by steric exclusion of cell adhesion to a KKTR-dependent cell adhesive site present within the N-terminal domain of TSP could explain the antiadhesive properties of DCN...
  15. ncbi request reprint [Bone hyperresorption in bone metastases]
    P Clezardin
    INSERM U 403, Faculte de Medecine Laennec, Lyon
    Presse Med 29:487-91. 2000
    ..This creates a vicious circle of mutual stimulation between bone destruction and tumor proliferation...
  16. ncbi request reprint Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone
    Isabelle Pécheur
    INSERM Research Unit 403, Faculty of Medicine Laennec, Lyon, France
    FASEB J 16:1266-8. 2002
    ..Overall, our findings suggest that integrin alpha(v)b3 expression in tumor cells accelerates the development of osteolytic lesions, presumably through increased invasion of and adhesion to bone...
  17. pmc How do bisphosphonates inhibit bone metastasis in vivo?
    Pierrick G Fournier
    Institut National de la Sante et de la Recherche Medicale, UMR 664, IFR62, Lyon, France
    Neoplasia 12:571-8. 2010
    ....
  18. ncbi request reprint Bisphosphonates in cancer therapy
    Verena Stresing
    INSERM, Research Unit U 664, Faculte de Medecine Laennec, Rue Guillaume Paradin, F 69372 Lyon Cedex 08, France
    Cancer Lett 257:16-35. 2007
    ..These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice...
  19. ncbi request reprint [Does tumor angiogenesis play a role in bone metastatic process?]
    Olivier Peyruchaud
    INSERM Research Unit 403 Faculté de Médecine Laënnec Rue Guillaume Paradin F 69372 Lyon
    Rev Med Suisse Romande 124:83-4. 2004
    ....
  20. ncbi request reprint [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties]
    Philippe Clezardin
    INSERM U 403, Faculté de Médecine Laënnec Rue Guillaume Paradin 69372 Lyon
    Prog Urol 13:28-35. 2003
  21. ncbi request reprint Anti-tumour activity of zoledronic acid
    Philippe Clezardin
    INSERM U664, Faculté de médecine RTH Laennec, Lyon, France
    Cancer Treat Rev 31:1-8. 2005
    ..The future challenge is to focus on optimizing dosing regimens and drug combinations to maximize the anti-tumour potential of zoledronic acid and to take advantage of the observed synergy with standard neoplastic agents...
  22. ncbi request reprint Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity
    Philippe Clezardin
    Institut National de la Sante et de la Recherche Medicale Research Unit 664, Laennec School of Medicine, Lyon, France
    Cancer Res 65:4971-4. 2005
    ..These preclinical findings reveal exciting ways of optimizing bisphosphonate therapy in oncology to fully exploit their antitumor potential...
  23. ncbi request reprint [Lysophosphatidic acid: a new link between blood platelets and bone metastasis]
    Olivier Peyruchaud
    Inserm U 664, Universite Claude Bernard Lyon 1, Faculte de Medecine Laennec, 69372 Lyon Cedex 08, France
    Med Sci (Paris) 21:353-5. 2005
  24. ncbi request reprint Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate
    Marc Colombel
    Institut National de la Sante et de la Recherche Medicale, Research Unit 403, Laennec School of Medicine, Lyon, France
    Cancer Res 65:300-8. 2005
    ..Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape...
  25. ncbi request reprint In vitro and in vivo antitumor effects of bisphosphonates
    Philippe Clezardin
    INSERM Research Unit 403, Faculty of Medicine Laennec, Lyon, France
    Curr Med Chem 10:173-80. 2003
    ..It will allow the design of clinical trials to investigate whether the antitumor activity of bisphosphonates can be realized in the clinical setting...
  26. ncbi request reprint Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis
    Florence Daubiné
    INSERM Research Unit U 664, Universite Claude Bernard Lyon 1, Lyon, France
    J Natl Cancer Inst 99:322-30. 2007
    ..We compared the antitumor effects of clinical dosing regimens of the bisphosphonates zoledronic acid and clodronate in a mouse model of bone metastasis...
  27. doi request reprint Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs
    V Stresing
    1 Biological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute IDIBELL, L Hospitalet de Llobregat, Barcelona, Spain 2 INSERM, UMR 664, IFR62, Laennec School of Medicine, Lyon, France
    Oncogene 32:724-35. 2013
    ..Overall, our results strongly suggest that PRDX2 is a targetable 'metabolic adaptor' driver protein implicated in the selective growth of metastatic cells in the lungs by protecting them against oxidative stress...
  28. ncbi request reprint Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
    P Clezardin
    INSERM U234, Pavillon F, Lyon, France
    Cancer Res 53:1421-30. 1993
    ..In this regard, the coexpression of TSP1 and CD36 may, in part at least, account for the variably invasive behavior of lobular carcinoma cells...
  29. ncbi request reprint Recent insights into the role of integrins in cancer metastasis
    P Clezardin
    INSERM Research Unit 403, Hopital Edouard Herriot, Lyon, France
    Cell Mol Life Sci 54:541-8. 1998
    ..Moreover, integrins may have a more complex role in cancer metastasis as they cooperate with serine proteases and metalloproteases to promote tumour cell invasion and angiogenesis. Finally, integrins favour tumor cell extravasation...
  30. doi request reprint Cathepsin K inhibitors as treatment of bone metastasis
    Céline Le Gall
    Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Curr Opin Support Palliat Care 2:218-22. 2008
    ..The purpose of this review is to consider cathepsin K, a cysteine protease produced by osteoclasts, as a therapeutic target for the treatment of patients with osteolytic bone metastases...
  31. doi request reprint Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo
    Pierrick G J Fournier
    Faculte de Medecine Laennec, Institut National de la Sante et de la Recherche Medicale, Research Unit UMR 664, Lyon, France
    Cancer Res 68:8945-53. 2008
    ..In conclusion, our study shows that decreasing the bone mineral affinity of bisphosphonates is an effective therapeutic strategy to inhibit skeletal tumor growth in vivo...
  32. ncbi request reprint A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden
    Céline Le Gall
    Institut National de la Sante et de la Recherche Medicale, UMR 664, IFR62, Lyon, France
    Cancer Res 67:9894-902. 2007
    ..Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases...
  33. ncbi request reprint Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo
    Aurelie Fontana
    INSERM Research Unit 664, Laennec School of Medicine, Lyon, France
    Int J Cancer 116:686-91. 2005
    ..Overall, these results suggest that a resistance may develop early in human breast cancers as a result of high in situ exposure to stromal TSP-1, leading to disease progression...
  34. doi request reprint Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention
    Florence Daubiné
    INSERM U664 and Université Claude Bernard Lyon 1, Faculte de Medecine Laennec, 69372 Lyon, France
    Biomaterials 30:6367-73. 2009
    ..Incorporation of the complexes into PEM nanoarchitectures covering bone implants appears of interest for in situ prevention of bone metastasis after ablation...
  35. ncbi request reprint Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases
    Yingshe Zhao
    Institut National de la Sante et de la Recherche Medicale, UMR 664, IFR62, Lyon, France
    Cancer Res 67:5821-30. 2007
    ..Overall, our data show that tumor alphavbeta3 integrin stands as a therapeutic target for the prevention of skeletal metastases...
  36. ncbi request reprint Complex formation of human thrombospondin with osteonectin
    P Clezardin
    Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine Alexis Carrel, Lyon, France
    Eur J Biochem 175:275-84. 1988
    ....
  37. ncbi request reprint Transmigration: a new property of mature multinucleated osteoclasts
    Frederic Saltel
    Laboratoire de Biologie Moleculaire de la Cellule, Lyon, France
    J Bone Miner Res 21:1913-23. 2006
    ..This activity is associated with c-src and MMPs and can be stimulated by bone metastatic breast cancer cells, a process blocked by bisphosphonate treatment...